Skip to main content

Dermatomyositis

Increased Risk of Dermatomyositis in Patients with Psoriasis: A Retrospective Cohort Study




Purpose


This study aimed to investigate the risk of dermatomyositis among patients with psoriasis in a large population.

Patients and Methods


Individuals aged ≥20 years with records in the TriNetX database from January 1, 2002 to December 31, 2022 were included. Diagnoses of psoriasis, non-psoriasis, dermatomyositis, and associated comorbidities were established using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) code. Patients who were diagnosed with dermatomyositis before the index date were excluded. Propensity score matching (PSM) was performed in a 1:1 ratio between the psoriasis group and non-psoriasis group. Kaplan–Meier curves were used to determine the cumulative incidence of dermatomyositis, and the Cox proportional hazard model was used to estimate the hazard ratio between the two groups.

Results


After PSM, 301018 individuals were included in the psoriasis and non-psoriasis groups, respectively. A higher risk of dermatomyositis was identified in patients with psoriasis than in those without (HR: 2.41, 95% CI: 2.01–2.89). This elevated risk was further confirmed in various subgroup analyses. Specifically, patients with PsA exhibited a higher incidence of dermatomyositis than those without PsA (HR, 1.73; 95% CI, 1.32–2.28). Patients treated with interleukin-17 inhibitors (IL-17i) showed a significantly higher risk of developing dermatomyositis compared to those naïve to biological agents (HR, 5.79; 95% CI, 1.57–21.31). In the European, Middle East, and Africa network and Asia-Pacific network, the risk of dermatomyositis in patients with psoriasis was higher than that in patients without psoriasis (HR (95% CI): 4.77 (1.40–16.10) and 2.50 (1.33–4.66), respectively).

Conclusion


This study revealed a higher risk of dermatomyositis in patients with psoriasis than in those without. The psoriatic patients with PsA or those who had received IL-17i treatment demonstrated a significantly higher risk of developing dermatomyositis.

dermatomyositis, inflammatory myopathy, autoimmune disease, muscle weakness, skin rash, heliotrope rash, Gottron’s papules, muscle biopsy, creatine kinase, anti-Mi-2 antibody, anti-MDA5 antibody, interstitial lung disease, calcinosis, dysphagia, proximal muscles, cutaneous manifestations, immunosuppressive therapy, corticosteroids, polymyositis, juvenile dermatomyositis

#dermatomyositis, #inflammatorymyopathy, #autoimmunedisease, #muscleweakness, #skinrash, #heliotroperash, #gottronspapules, #musclebiopsy, #creatinekinase, #antimi2, #antimda5, #interstitiallungdisease, #calcinosis, #dysphagia, #proximalmuscles, #cutaneousmanifestations, #immunosuppressive, #corticosteroids, #polymyositis, #juveniledermatomyositis

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Genetic Test

Genetic test eliminates progressive retinal atrophy in English shepherd dogs Researchers at the University of Cambridge recently published their findings in Genes after identifying the genetic mutation that is causing progressive retinal atrophy (PRA) in English shepherd dogs. PRA is a group of inherited diseases causing progressive degeneration of the light sensitive cells within the back of the eyes. When it comes to PRA in dogs, they are born with normal vision but by the age of 4-5 they go totally blind with no treatment. According to the release, by identifying the canines carrying this disease before they lose vision, this can be then used as a tool to guide breeding decisions to prevent the passing of the disease onto puppies.1 Historically, owners did not realize their dog had PRA until they were middle-aged, which means it could have been passed on to puppies if they had bred, making this a hard disease to control. “Once the dog’s eyesight starts to fail there’s no treatment ...
Post a Comment
Read more